OCULAR THERAPEUTIX INC (OCUL) Stock Price & Overview
NASDAQ:OCUL • US67576A1007
Current stock price
The current stock price of OCUL is 8.49 USD. Today OCUL is up by 1.92%. In the past month the price decreased by -17.81%. In the past year, price increased by 33.6%.
OCUL Key Statistics
- Market Cap
- 1.848B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.44
- Dividend Yield
- N/A
OCUL Stock Performance
OCUL Stock Chart
OCUL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OCUL. When comparing the yearly performance of all stocks, OCUL turns out to be only a medium performer in the overall market: it outperformed 44.74% of all stocks.
OCUL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OCUL. While OCUL seems to be doing ok healthwise, there are quite some concerns on its profitability.
OCUL Earnings
On February 5, 2026 OCUL reported an EPS of -0.29 and a revenue of 13.25M. The company beat EPS expectations (12.73% surprise) and missed revenue expectations (-19.46% surprise).
OCUL Forecast & Estimates
18 analysts have analysed OCUL and the average price target is 26.35 USD. This implies a price increase of 210.37% is expected in the next year compared to the current price of 8.49.
For the next year, analysts expect an EPS growth of 5.48% and a revenue growth 0.34% for OCUL
OCUL Groups
Sector & Classification
OCUL Financial Highlights
Over the last trailing twelve months OCUL reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 2.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.91% | ||
| ROE | -40.64% | ||
| Debt/Equity | 0.11 |
OCUL Ownership
OCUL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCUL
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 325 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Company Info
IPO: 2014-07-25
OCULAR THERAPEUTIX INC
15 Crosby Drive
Bedford MASSACHUSETTS 01730 US
CEO: Antony Mattessich
Employees: 325
Phone: 17813574000
OCULAR THERAPEUTIX INC / OCUL FAQ
What does OCULAR THERAPEUTIX INC do?
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 325 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Can you provide the latest stock price for OCULAR THERAPEUTIX INC?
The current stock price of OCUL is 8.49 USD. The price increased by 1.92% in the last trading session.
What is the dividend status of OCULAR THERAPEUTIX INC?
OCUL does not pay a dividend.
What is the ChartMill rating of OCULAR THERAPEUTIX INC stock?
OCUL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of OCULAR THERAPEUTIX INC (OCUL) based on its PE ratio?
OCULAR THERAPEUTIX INC (OCUL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.44).
Should I buy OCUL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OCUL.
What is the market capitalization of OCUL stock?
OCULAR THERAPEUTIX INC (OCUL) has a market capitalization of 1.85B USD. This makes OCUL a Small Cap stock.